Related Experiment Videos
Inhibition of endogenous TNF formation by pentoxifylline
P Zabel1, F U Schade, M Schlaak
1Department of Clinical Medicine, Forschungsinstitut Borstel, Germany.
Abstract:
During the last decade cytokines were recognized as focal components in acute and chronic inflammatory processes. The growing knowledge about these agents stimulated efforts to pharmacologically control their synthesis and action in clinical situations. Various rational approaches to these issues including selective antibodies or receptor antagonists are at present under clinical investigation. Recently, in our institute evidence was raised that pentoxifylline is able to suppress the synthesis of tumor necrosis factor-alpha in cell cultures, and in vivo, and to protect experimental animals against endotoxin shock. Extended studies in human experimental endotoxemia showed that pentoxifylline decreased circulating TNF without affecting endogenous formation of interleukins. The potency of this drug to interfere with TNF synthesis could also be demonstrated in cases of acute and chronic cytokine release-syndromes such as OKT3 first-dose reaction and severe pulmonary tuberculosis, respectively. In conclusion, we suggest that pentoxifylline may improve therapeutic strategies in septic syndrome and other diseases in which TNF represents a causative pathophysiological factor.
Insights
Pentoxifylline suppresses tumor necrosis factor-alpha (TNF) synthesis, offering protection against endotoxin shock. This drug may improve treatments for conditions where TNF is a key factor, like septic syndrome.
Area of Science:
- Immunology
- Pharmacology
Background:
- Cytokines are key players in inflammatory processes.
- Pharmacological control of cytokine synthesis and action is an active research area.
- Pentoxifylline has shown potential in modulating cytokine activity.
Purpose of the Study:
- To investigate the effect of pentoxifylline on tumor necrosis factor-alpha (TNF) synthesis and its clinical implications.
- To evaluate pentoxifylline's efficacy in managing conditions associated with excessive cytokine release.
Main Methods:
- In vitro and in vivo studies assessing pentoxifylline's impact on TNF synthesis.
- Experimental human endotoxemia models to measure circulating TNF levels.
- Clinical observations in cytokine release syndromes (e.g., OKT3 reaction, tuberculosis).
Main Results:
- Pentoxifylline suppressed TNF synthesis in cell cultures and in vivo.
- The drug protected against endotoxin shock in experimental animals.
- In human endotoxemia, pentoxifylline reduced circulating TNF without altering interleukin levels.
- Efficacy was observed in acute and chronic cytokine release syndromes.
Conclusions:
- Pentoxifylline demonstrates potent inhibition of TNF synthesis.
- It offers protective effects against endotoxin-induced shock.
- Pentoxifylline may be a valuable therapeutic agent for septic syndrome and other TNF-mediated diseases.